Key Highlights
- QuidelOrtho shares plummeted as management slashed full-year 2026 revenue guidance to $2.52-$2.60 billion.
- Adjusted EPS guidance was cut to $0.65-$0.90, down significantly from previous ranges.
- The downward revision stems from IVD pricing headwinds in China.
- Waning international respiratory demand also contributed, overshadowing a Q2 revenue beat.
QuidelOrtho (NASDAQ: QDEL) shares plummeted as management slashed full-year 2026 revenue guidance to $2.52 billion to $2.60 billion and adjusted EPS guidance to $0.65 to $0.90, down significantly from previous ranges.
What Happened
The downward revision stems from IVD pricing headwinds in China and waning international respiratory demand, overshadowing a second-quarter revenue beat.
Market Reaction
Shares fell sharply as investors focused on the scale of the guidance cuts, which outweighed the positive impact of the reported Q2 revenue beat.
Outlook
Continued monitoring of IVD pricing trends in China and international respiratory demand is likely to remain the key factors shaping sentiment toward QuidelOrtho's stock going forward.
Why did QuidelOrtho shares plummet?
Shares fell after management slashed full-year 2026 revenue and adjusted EPS guidance, citing IVD pricing headwinds in China and waning international respiratory demand.
What is QuidelOrtho's updated full-year 2026 revenue guidance?
$2.52 billion to $2.60 billion.
Did QuidelOrtho beat estimates in Q2?
Yes, the company reported a second-quarter revenue beat, though it was overshadowed by the guidance cut.






Please wait processing your request...